REFERENCES
- Abbott F. S., Anari M. R. Chemistry and biotransformation. Milestones in Drug Therapy. Valproate, W. Loscher. Birkhauser Verlag, Basel 1999; 47–75
- Afzal M., Matsugo S., Sasai M., Xu B., Aoyama K., Takeuchi T. Method to overcome photoreaction, a serious drawback to the use of dichlorofluorescin in evaluation of reactive oxygen species. Biochem. Biophys. Res. Commun. 2003; 304: 619–624, [INFOTRIEVE], [CSA]
- Appleton R. E., Farrell K., Applegarth D. A., Dimmick J. E., Wong L. T. K., Davidson A. G. F. The high incidence of valproate hepatotoxicity in infants may relate to familial metabolic defects. Can. J. Neurol. Sci. 1990; 17: 145–148, [INFOTRIEVE], [CSA]
- Bass D. A., Parce J. W., Dechatelet L. R., Szejda P., Seeds M. C., Thomas M. Flow cytometric studies of oxidative product formation by neutrophils: a graded response to membrane stimulation. J. Immunol. 1983; 130: 1910–1917, [INFOTRIEVE], [CSA]
- Bjorge S. M., Baillie T. A. Inhibition of medium-chain fatty acid beta-oxidation in vitro by valproic acid and its unsaturated metabolite, 2-n-propyl-4-pentenoic acid. Biochem. Biophys. Res. Commun. 1985; 132: 245–252, [INFOTRIEVE], [CSA], [CROSSREF]
- Boelsterli U. A. Diclofenac-induced liver injury: a paradigm of idiosyncratic drug toxicity. Toxicol. Appl. Pharmacol. 2003; 192: 307–322, [INFOTRIEVE], [CSA], [CROSSREF]
- Bryant III A. E., Dreifuss F. E. Valproic acid hepatic fatalities. III. U.S. experiences since 1986. Neurology 1996; 46: 465–469, [CSA]
- Buchi K. N., Gray P. D., Rollins D. E., Tolman K. G. Protection against sodium valproate injury isolated hepatocytes by a-tocopherol and N, N′-diphenyl-p-phenylenediamine. J. Clin. Pharmacol. 1984; 24: 148–154, [INFOTRIEVE], [CSA]
- Burkitt M. J., Wardman P. Cytochrome c is a potent catalyst of dichlorofluorescin oxidation: implications for the role of reactive oxygen species in apoptosis. Biochem. Biophys. Res. Commun. 2001; 282: 329–333, [INFOTRIEVE], [CSA], [CROSSREF]
- Clarkson A., Choonara I. Surveillance for fatal suspected adverse drug reactions in the UK. Arch. Dis. Child. 2002; 87: 462–467, [INFOTRIEVE], [CSA], [CROSSREF]
- Collins A. R., Cadet J., Moller L., Poulsen H. E., Vina J. Are we sure we know how to measure 8-oxo-7,8-dihydroguanine in DNA from human cells?. Arch. Biochem. Biophys. 2004; 423: 57–65, [INFOTRIEVE], [CSA], [CROSSREF]
- Cotariu D., Evans S., Zaidman J. L., Marcus O. Early changes in hepatic redox homeostasis following treatment with a single dose of valproic acid. Biochem. Pharmacol. 1990; 40: 589–593, [INFOTRIEVE], [CSA], [CROSSREF]
- Coulter D. L. Carnitine deficiency: a possible mechanism for valproate hepatotoxicity. Lancet 1984; 1: 689, [INFOTRIEVE], [CSA], [CROSSREF]
- Cracowski J. L., Durand T., Bessard G. Isoprostanes as a biomarker of lipid peroxidation in humans: physiology, pharmacology and clinical implications. Trends Pharmacol. Sci. 2002; 23: 360–366, [INFOTRIEVE], [CSA], [CROSSREF]
- Davi G., Ciabattoni G., Consoli A., Mezzetti A., Falco A., Santarone S., Pennese E., Vitacolonna E., Bucciarelli T., Costantini F., Capani F., Patrono C. In vivo formation of 8-iso-prostaglandin F2-alpha and platelet activation in diabetes mellitus: effects of improved metabolic control and vitamin E supplementation. Circulation 1999; 99: 224–229, [INFOTRIEVE], [CSA]
- Eadie M. J., Hooper W. D., Dickinson R. G. Valproate-associated hepatotoxicity and its biochemical mechanisms. Med. Toxicol. 1988; 3: 85–106, [CSA]
- Fam S. S., Morrow J. D. The isoprostanes: unique products of arachidonic acid oxidation - a review. Curr. Med. Chem. 2003; 10: 1723–1740, [INFOTRIEVE], [CSA], [CROSSREF]
- Farrell K., Abbott F. S. Role of N-acetylcysteine in the treatment of valproate hepatotoxicity. Idiosyncratic Reactions to Valproate: Clinical Risk Patterns and Mechanisms of Toxicity, R. H. Levy, J. K. Penry. Raven Press, New York 1991; 149–153
- Fromenty B., Pessayre D. Impaired mitochondrial function in microvesicular steatosis. Effects of drugs, ethanol, hormones and cytokines. J. Hepatol. 1997; 26(Suppl 2)43–53, [INFOTRIEVE], [CSA], [CROSSREF]
- Genton P., Gelisse P. Valproic acid adverse effects. Antiepileptic Drugs 5th, R. H. Levy, R. H. Mattson, B. S. Meldrum, E. Perucca. Lippincott Williams & Willkins, Philadelphia 2002; 837–851
- Gerber N., Dickinson R. G., Harland R. C., Lynn R. K., Houghton L. D., Antonias J. I., Schimschock J. C. Reye-like syndrome associated with valproic acid therapy. J. Pediatr. 1979; 95: 142–144, [INFOTRIEVE], [CSA], [CROSSREF]
- Gopaul S., Farrell K., Abbott F. Effects of age and polytherapy, risk factors of valproic acid (VPA) hepatotoxicity, on the excretion of thiol conjugates of (E)-2,4-diene VPA in people with epilepsy taking VPA. Epilepsia 2003; 44: 322–328, [INFOTRIEVE], [CSA], [CROSSREF]
- Gopaul V. S., Farrell K., Abbott F. S. Gas chromatography/negative ion chemical ionization mass spectrometry and liquid chromatography/electrospray ionization tandem mass spectrometry quantitative profiling of N-acetylcysteine conjugates of valproic acid in urine: application in drug metabolism studies in humans. J. Mass Spectrom. 2000a; 35: 698–704, [INFOTRIEVE], [CSA], [CROSSREF]
- Gopaul V. S., Farrell K., Abbott F. S. Identification and characterization of N-acetylcysteine conjugates of valproic acid in humans and animals. Drug Metab. Dispos. 2000b; 28: 823–832, [INFOTRIEVE], [CSA]
- Gottlicher M., Minucci S., Zhu P., Kramer O. H., Schimpf A., Giavara S., Sleeman J. P., Lo Coco F., Nervi C., Pelicci P. G., Heinzel T. Valproic acid defines a novel class of HDAC inhibitors inducing differentiation of transformed cells. EMBO J. 2001; 20: 6969–6978, [INFOTRIEVE], [CSA], [CROSSREF]
- Graf W. D., Oleinik O. E., Glauser T. A., Maertens P., Eder D. N., Pippenger C. E. Altered antioxidant enzyme activities in children with a serious adverse experience related to valproic acid therapy. Neuropediatrics 1998; 29: 195–201, [INFOTRIEVE], [CSA]
- Granneman G. R., Wang S., Kesterson J. W., Machinist J. M. The hepatotoxicity of valproic acid and its metabolites in rats. II. Intermediary and valproic acid metabolism. Hepatology 1984; 4: 1153–1158, [INFOTRIEVE], [CSA]
- Griffith O. W. Depletion of glutathione by inhibition of biosynthesis. Methods Enzymol. 1981; 77: 59–64, [INFOTRIEVE], [CSA]
- Grillo M. P., Chiellini G., Tonelli M., Benet L. Z. Effect of α-fluorination of valproic acid on valproyl-S-acyl-CoA formation in vivo in rats. Drug Metab. Dispos. 2001; 29: 1210–1215, [INFOTRIEVE], [CSA]
- Grzelak A., Rychlik B., Bartosz G. Light-dependent generation of reactive oxygen species in cell culture media. Free Radic. Biol. Med. 2001; 30: 1418–1425, [INFOTRIEVE], [CSA], [CROSSREF]
- Halliwell B., Whiteman M. Measuring reactive species and oxidative damage in vivo and in cell culture: how should you do it and what do the results mean?. Br. J. Pharmacol. 2004; 142: 231–235, [INFOTRIEVE], [CSA], [CROSSREF]
- Hamed S. A., Abdellah M. M., El-Melegy N. Blood levels of trace elements, electrolytes, and oxidative stress/antioxidant systems in epileptic patients. J. Pharmacol. Sci. 2004; 96: 465–473, [INFOTRIEVE], [CSA], [CROSSREF]
- Han D., Hanawa N., Saberi B., Kaplowitz N. Role of gluathione redox status in liver injury. Am. J. Physiol. Gastrointest. Liver Physiol. 2006; 291: G1–G7, [INFOTRIEVE], [CSA], [CROSSREF]
- Hill D. B., Awad J. A. Increased urinary F2-isoprostane excretion in alcoholic liver disease. Free Radic. Biol. Med. 1999; 26: 656–660, [INFOTRIEVE], [CSA], [CROSSREF]
- Hurd R. W., Van Rinsvelt H. A., Wilder B. J., Karas B., Maenhaut W., De Reu L. Selenium, zinc, and copper changes with valproic acid: possible relation to drug side effects. Neurology 1984; 34: 1393–1395, [INFOTRIEVE], [CSA]
- Jakubowski W., Bartosz G. 2,7-Dichlorofluorescin oxidation and reactive oxygen species: what does it measure?. Cell Biol. Int. 2000; 24: 757–760, [INFOTRIEVE], [CSA], [CROSSREF]
- Jeavons P. M. Non-dose-related side effects of valproate. Epilepsia 1984; 25(Suppl 1)S50–S55, [INFOTRIEVE], [CSA]
- Jezequel A. M., Bonazzi P., Novelli G., Venturini C., Orlandi F. Early structural and functional changes in liver of rats treated with a single dose of valproic acid. Hepatology 1984; 4: 1159–1166, [INFOTRIEVE], [CSA]
- Jurima-Romet M., Abbott F. S., Tang W., Huang H. S., Whitehouse L. W. Cytotoxicity of unsaturated metabolites of valproic acid and protection by vitamins C and E in glutathione-depleted rat hepatocytes. Toxicology 1996; 112: 69–85, [INFOTRIEVE], [CSA], [CROSSREF]
- Kassahun K., Farrell K., Abbott F. S. Identification and characterization of the glutathione and N-acetylcysteine conjugates of (E)-2-propyl-2,4-pentadienoic acid, a toxic metabolite of valproic acid, in rats and humans. Drug Metab. Dispos. 1991; 19: 525–535, [INFOTRIEVE], [CSA]
- Kassahun K., Hu P., Grillo M. P., Davis M. R., Jin L., Baillie T. A. Metabolic activation of unsaturated derivatives of valproic acid. Identification of novel glutathione adducts formed through coenzyme A-dependent and -independent processes. Chem. Biol. Interact. 1994; 90: 253–275, [INFOTRIEVE], [CSA], [CROSSREF]
- Kesterson J. W., Granneman G. R., Machinist J. M. The hepatotoxicity of valproic acid and its metabolites in rats. I. Toxicologic, biochemical and histopathologic studies. Hepatology 1984; 4: 1143–1152, [INFOTRIEVE], [CSA]
- Kingsley E., Gray P., Tolman K. G., Tweedale R. The toxicity of metabolites of sodium valproate in cultured hepatocytes. J. Clin. Pharmacol. 1983; 23: 178–185, [INFOTRIEVE], [CSA]
- Klee S., Johanssen S., Ungemach F. R. Evidence for a trigger function of valproic acid in xenobiotic-induced hepatotoxicity. Pharmacol. Toxicol. 2000; 87: 89–95, [INFOTRIEVE], [CSA], [CROSSREF]
- Konig S. A., Schenk M., Sick C., Holm E., Heubner C., Weiss A., Konig I., Hehlmann R. Fatal liver failure associated with valproate therapy in a patient with Friedreich's disease: review of valproate hepatotoxicity in adults. Epilepsia 1999; 40: 1036–1040, [INFOTRIEVE], [CSA], [CROSSREF]
- Konig S. A., Siemes H., Blaker F., Boenigk E., Grob-Selbeck G., Hanefeld F., Hass N., Kohler B., Koelfen W., Korinthenberg R., Kurek E., Lenard H. G., Penin H., Penzien J. M., Schunke W., Schultze C., Stephani U., Stute M., Traus M., Weinmann H. M., Scheffner D. Severe hepatotoxicity during valproate therapy: an update and report of eight new fatalities. Epilepsia 1994; 35: 1005–1015, [INFOTRIEVE], [CSA], [CROSSREF]
- Kopani M., Celec P., Danisovic L., Michalka P., Biro C. Oxidative stress and electron spin resonance. Clin. Chim. Acta 2006; 364: 61–66, [INFOTRIEVE], [CSA], [CROSSREF]
- Kossak B. D., Schmidt-Sommerfeld E., Schoeller D. A., Rinaldo P., Penn D., Tonsgard J. H. Impaired fatty acid oxidation in children on valproic acid and the effect of L‐carnitine. Neurology 1993; 43: 2362–2368, [INFOTRIEVE], [CSA]
- Kuhara T., Inoue Y., Matsumoto M., Shinka T., Matsumoto I., Kawahara N., Sakura N. Markedly increase ω-oxidation of valproate in fluminant hepatic failure. Epilepsia 1990; 31: 214–217, [INFOTRIEVE], [CSA]
- Kurekci A. E., Alpay F., Tanindi S., Gokcay E., Ozcan O., Akin R., Isimer A., Sayal A. Plasma trace element, plasma glutathione peroxidase, and superoxide dismutase levels in epileptic children receiving antiepileptic drug therapy. Epilepsia 1995; 36: 600–604, [INFOTRIEVE], [CSA], [CROSSREF]
- Lehrman G., Hogue I. B., Palmer S., Jennings C., Spina C. A., Wiegand A., Landay A. L., Coombs R. W., Richman D. D., Mellors J. W., Coffin J. M., Bosch R. J., Margolis D. M. Depletion of latent HIV-1 infection in vivo: a proof-of-concept study. Lancet 2005; 366: 549–555, [INFOTRIEVE], [CSA], [CROSSREF]
- Lewis J. H., Zimmerman H. J., Garrett C. T., Rosenberg E. Valproate-induced hepatic steatogenesis in rats. Hepatology 1982; 2: 870–873, [INFOTRIEVE], [CSA]
- Loscher W. Valproate: a reappraisal of its pharmacodynamic properties and mechanisms of action. Prog. Neurobiol. 1999; 58: 31–59, [INFOTRIEVE], [CSA], [CROSSREF]
- Michoulas A., Tong V., Teng X. W., Chang T. K. H., Abbott F. S., Farrell K. Oxidative stress in children receiving valproic acid. J. Pediatr. 2006, in press[CSA]
- Minucci S., Pelicci P. G. Histone deacetylase inhibitors and the promise of epigenetic (and more) treatment of cancer. Nat. Rev. Cancer 2006; 6: 38–51, [INFOTRIEVE], [CSA]
- Murugesan V., Subramanian P. Enhancement of circulatory antioxidants by α-ketoglutarate during sodium valproate treatment in Wistar rats. Pol. J. Pharmacol. 2003; 55: 31–36, [INFOTRIEVE], [CSA]
- Niketic V., Ristic S., Saicic Z. S., Spasic M., Buzadzic B., Stojkovic M. Activities of antioxidant enzymes and formation of the glutathione adduct of hemoglobin (Hb ASSG) in epileptic patients with long-term antiepileptic therapy. Farmaco 1995; 50: 811–813, [INFOTRIEVE], [CSA]
- O'Malley Y. Q., Reszka K. J., Britigan B. E. Direct oxidation of 2′,7′-dichlorodihydrofluorescein by pyocyanin and other redox-active compounds independent of reactive oxygen species production. Free Radic. Biol. Med. 2004; 36: 90–100, [INFOTRIEVE], [CSA], [CROSSREF]
- Olson M. J., Handler J. A., Thurman R. G. Mechanism of zone-specific hepatic steatosis caused by valproate: inhibition of ketogenesis in periportal regions of the liver lobule. Mol. Pharmacol. 1986; 30: 520–525, [INFOTRIEVE], [CSA]
- Ono H., Sakamoto A., Sakura N. Plasma total glutathione concentrations in epileptic patients taking anticonvulsants. Clin. Chim. Acta 2000; 298: 135–143, [INFOTRIEVE], [CSA], [CROSSREF]
- Perucca E. Pharmacological and therapeutic properties of valproate. A summary after 35 years of clinical experience. CNS Drugs 2002; 16: 695–714, [INFOTRIEVE], [CSA], [CROSSREF]
- Phiel C. J., Zhang F., Huang E. Y., Guenther M. G., Lazar M. A., Klein P. S. Histone deacetylase is a direct target of valproic acid, a potent anticonvulsant, mood stabilizer, and teratogen. J. Biol. Chem. 2001; 276: 36734–36741, [INFOTRIEVE], [CSA], [CROSSREF]
- Pippenger C. E., Meng X., Rothner A. D., Cruse R. P., Erenberg G., Solano R. Free radical scavenging enzyme activity profiles in risk assessment of idiosyncratic drug reactions. Idiosyncratic Reactions to Valproate: Clinical Risk Patterns and Mechanisms of Toxicity, R. H. Levy, J. K. Penry. Raven Press, New York 1991; 75–88
- Plummer J. L., Smith B. R., Sies H., Bend J. R. Chemical depletion of glutathione in vivo. Methods Enzymol. 1981; 77: 50–59, [INFOTRIEVE], [CSA]
- Ponchaut S., van Hoof F., Veitch K. In vitro effects of valproate and valproate metabolites on mitochondrial oxidations. Relevance to CoA sequesteration to the observed inhibitions. Biochem. Pharmacol. 1992; 43: 2435–2442, [INFOTRIEVE], [CSA], [CROSSREF]
- Raza M., Al-Bekairi A. M., Ageel A. M., Qureshi S. Biochemical basis of sodium valproate hepatotoxicity and renal tubular disorder: time dependence of peroxidative injury. Pharmacol. Res. 1997; 35: 153–157, [INFOTRIEVE], [CSA], [CROSSREF]
- Reilly M., Delanty N., Lawson J. A., Fitzgerald G. A. Modulation of oxidant stress in vivo in chronic cigarette smokers. Circulation 1996; 94: 19–25, [INFOTRIEVE], [CSA]
- Scheffner D., Konig S., Rauterberg-Ruland I., Kochen W., Hofmann W. J., Unkelbach S. Fatal liver failure in 16 children with valproate therapy. Epilepsia 1988; 29: 530–542, [INFOTRIEVE], [CSA]
- Schulpis K. H., Lazaropoulou C., Regoutas S., Karikas G. A., Margeli A., Tsakiris S., Papassotiriou I. Valproic acid monotherapy induces DNA oxidative damage. Toxicology 2006; 217: 228–232, [INFOTRIEVE], [CSA], [CROSSREF]
- Seckin S., Basaran-Kucukgergin C., Uysal M. Effect of acute and chronic administration of sodium valproate on lipid peroxidation and antioxidant system in rat liver. Pharmacol. Toxicol. 1999; 85: 294–298, [INFOTRIEVE], [CSA]
- Siemes H., Nau H., Schultze K., Wittfoht W., Drews E., Penzien J., Seidel U. Valproate (VPA) metabolites in various clinical conditions of probable VPA-associated hepatotoxicity. Epilepsia 1993; 34: 332–346, [INFOTRIEVE], [CSA], [CROSSREF]
- Tabatabaei A. R., Thies R. L., Abbott F. S. Assessing the mechanism of metabolism-dependent valproic acid-induced in vitro cytotoxicity. Chem. Res. Toxicol. 1999; 12: 323–330, [INFOTRIEVE], [CSA], [CROSSREF]
- Tafazoli S., Spehar D. D., O'Brien P. J. Oxidative stress mediated idiosyncratic drug toxicity. Drug Metab. Rev. 2005; 37: 311–325, [INFOTRIEVE], [CSA]
- Tang W., Borel A. G., Fujimiya T., Abbott F. S. Fluorinated analogues as mechanistic probes in valproic acid hepatotoxicity: hepatic microvesicular steatosis and glutathione status. Chem. Res. Toxicol. 1995; 8: 671–682, [INFOTRIEVE], [CSA], [CROSSREF]
- Tang W., Palaty J., Abbott F. S. Time course of α-fluorinated valproic acid in mouse brain and serum and its effect on synaptosomal γ-aminobutyric acid levels in comparison to valproic acid. J. Pharmacol. Exp. Ther. 1997; 282: 1163–1172, [INFOTRIEVE], [CSA]
- Thurston J. H., Carroll J. E., Hauhart R. E., Schiro J. A. A single therapeutic dose of valproate affects liver carbohydrate, fat, adenylate, amino acid, coenzyme A, and carnitine metabolism in infant mice: possible clinical significance. Life Sci. 1985; 36: 1643–1651, [INFOTRIEVE], [CSA], [CROSSREF]
- Tong V., Chang T. K. H., Chen J., Abbott F. S. The effect of valproic acid on hepatic and plasma levels of 15-F2t-isoprostane in rats. Free Radic. Biol. Med. 2003; 34: 1435–1446, [INFOTRIEVE], [CSA], [CROSSREF]
- Tong V., Teng X. W., Chang T. K. H., Abbott F. S. Valproic acid I. Time course of lipid peroxidation biomarkers, liver toxicity, and valproic acid metabolites levels in rats. Toxicol. Sci. 2005a; 86: 427–435, [INFOTRIEVE], [CSA], [CROSSREF]
- Tong V., Teng X. W., Chang T. K. H., Abbott F. S. Valproic Acid II. Effect on oxidative stress, mitochondrial membrane potential, and cytotoxicity in glutathione-depleted rat hepatocytes. Toxicol. Sci. 2005b; 86: 436–443, [INFOTRIEVE], [CSA], [CROSSREF]
- Tong V., Teng X. W., Karagiozov S., Chang T. K. H., Abbott F. S. Valproic acid glucuronidation is associated with increases in 15-F2t-isoprostane in rats. Free Radic. Biol. Med. 2005c; 38: 1471–1483, [INFOTRIEVE], [CSA], [CROSSREF]
- Ubeda N., Alonso-Aperte E., Varela-Moreiras G. Acute valproate administration impairs methionine metabolism in rats. J. Nutr. 2002; 132: 2737–2742, [INFOTRIEVE], [CSA]
- Van den Branden C., Roels F. Peroxisomal beta-oxidation and sodium valproate. Biochem. Pharmacol. 1985; 34: 2147–2149, [INFOTRIEVE], [CSA], [CROSSREF]
- Verrotti A., Basciani F., Trotta D., Pomilio M. P., Morgese G., Chiarelli F. Serum copper, zinc, selenium, glutathione peroxidase and superoxide dismutase levels in epileptic children before and after 1 year of sodium valproate and carbamazepine therapy. Epilepsy Res. 2002; 48: 71–75, [INFOTRIEVE], [CSA], [CROSSREF]
- Walgren J. L., Mitchell M. D., Thompson D. C. Role of metabolism in drug-induced idiosyncratic hepatotoxicity. Crit. Rev. Toxicol. 2005; 35: 325–361, [INFOTRIEVE], [CSA]
- Wilder B. J., Hurd R. W. Free radical scavenger deficiency and valproic acid. Idiosyncratic Reactions to Valproate: Clinical Risk Assessments and Mechanisms of Toxicity, R. H. Levy, J. K. Penry. Raven Press, New York 1991; 89–95
- Yuksel A., Cengiz M., Seven M., Ulutin T. Changes in the antioxidant system in epileptic children receiving antiepileptic drugs: two-year prospective studies. J. Child Neurol. 2001; 16: 603–606, [INFOTRIEVE], [CSA]
- Zafrani E. S., Berthelot P. Sodium valproate in the induction of unusual hepatotoxicity. Hepatology 1982; 2: 648–649, [INFOTRIEVE], [CSA]
- Zimmerman H. J., Ishak K. G. Valproate-induced hepatic injury: analysis of 23 fatal cases. Hepatology 1982; 2: 591–597, [INFOTRIEVE], [CSA]